Índice Bovespa

US Dollar vs BRL

Aumente o nível de sua negociação com nossas ferramentas poderosas e insights em tempo real, tudo em um só lugar.

Cadastre-se

Início
Investir
Ações
EUA
NASDAQ
Allos Therapeutics, Inc. (MM) (ALTH)
Allos Therapeutics, Inc. (MM) (ALTH) Notícias

ALTH

Allos Therapeutics, Inc. (MM) (ALTH)

Allos Therapeutics, Inc. (MM)

De:

Notícias regulamentadas

Procure um Texto:

Ordenação:

Notícias não regulamentadas

Apresentando as notícias mais relevantes sobre:NASDAQ:ALTH

<< Anterior 1 2 3 4 5 6 7 8 9 10 11 12 13 Próxima >>

Data	Hora	Fonte	Título	Código	Companhia
21/10/2005	14:02	PR Newswire (US)	Allos Therapeutics Announces Dismissal of Securities Class Action Lawsuit	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
13/10/2005	10:01	PR Newswire (US)	Allos Therapeutics to Present at the 2005 BIO Investor Forum	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
11/10/2005	19:06	PR Newswire (US)	Allos Therapeutics Announces Withdrawal of European Marketing Authorization Application for REVAPROXYN(TM)	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
22/09/2005	10:00	PR Newswire (US)	Allos Therapeutics to Present at the UBS Global Life Sciences Conference	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
07/09/2005	10:02	PR Newswire (US)	Allos Therapeutics to Present at the Bear Stearns Healthcare Conference	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
01/09/2005	10:00	PR Newswire (US)	Results Published in Journal of Clinical Oncology Demonstrate Survival Benefit of EFAPROXYN(TM) in Treating NSCLC Patients Recei	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
08/08/2005	10:01	PR Newswire (US)	Allos Therapeutics Reports Second Quarter 2005 Financial Results	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
16/06/2005	16:28	PR Newswire (US)	Allos Therapeutics and Hovione Enter Into Manufacturing Agreement for EFAPROXYN(TM) Bulk Drug Substance	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
19/05/2005	19:46	PR Newswire (US)	Allos Therapeutics Announces Stockholder Approval of Share Exchange	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
19/05/2005	10:00	PR Newswire (US)	Allos Therapeutics to Present at the Needham & Company Biotechnology Conference	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
05/05/2005	10:01	PR Newswire (US)	Allos Therapeutics Reports First Quarter 2005 Financial Results	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
11/03/2005	08:00	PR Newswire (US)	Allos Therapeutics to Present at SG Cowen's Healthcare Conference	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
03/03/2005	08:02	PR Newswire (US)	Allos Therapeutics Reports 2004 Financial Results	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
03/03/2005	08:00	PR Newswire (US)	Allos Therapeutics Announces $50 Million Financing	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
20/01/2005	11:00	PR Newswire (US)	Allos Therapeutics Initiates Phase 1 PDX Study in Patients With Non-Small Cell Lung Cancer	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
06/01/2005	11:01	PR Newswire (US)	Allos Therapeutics Announces Expansion of ENRICH Trial Into Europe	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
16/12/2004	11:00	PR Newswire (US)	Allos Therapeutics Licenses New Cancer Compound	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
09/12/2004	14:38	PR Newswire (US)	Allos Therapeutics Investigator Presents Updated Survival Results From Phase III REACH Study at San Antonio Breast Cancer Sympos	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
17/11/2004	09:00	PR Newswire (US)	Allos Therapeutics to Present at Credit Suisse First Boston's Healthcare Conference	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
11/11/2004	11:01	PR Newswire (US)	Allos Therapeutics Announces Presentation on EFAPROXYN(TM) at Chemotherapy Foundation Symposium XXII	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
08/11/2004	19:30	PR Newswire (US)	Allos Therapeutics Reports Third Quarter 2004 Financial Results	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
04/11/2004	19:30	PR Newswire (US)	Allos Therapeutics To Hold Third Quarter 2004 Financial Results Conference Call and Webcast on Tuesday, November 9	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
31/10/2004	11:00	PR Newswire (US)	Updated Results of Allos' Phase 3 Reach Study Confirm Survival Benefit in Patients With Brain Metastases From Breast Cancer	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
20/10/2004	10:00	PR Newswire (US)	Allos Therapeutics to Present at Rodman & Renshaw Conference	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
13/10/2004	10:00	PR Newswire (US)	Allos Therapeutics Appoints Marc Graboyes as Vice President, General Counsel	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
05/10/2004	18:30	PR Newswire (US)	Response at Three-Months Post WBRT Found to be Statistically Significant Predictor of Survival in Largest Ever Randomized Study	NASDAQ:ALTH
04/10/2004	16:30	PR Newswire (US)	Prognostic Factors Influencing Survival in Patients with Brain Metastases Identified in Largest Ever Randomized Study	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
03/08/2004	17:23	PR Newswire (US)	Allos Therapeutics Receives Orphan Drug Designation From U.S. FDA for EFAPROXYN(TM)	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
03/08/2004	09:45	PR Newswire (US)	Reminder - Allos Therapeutics to Hold Q2 2004 Financial Results Conference Call and Webcast on Tuesday, August 3	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
03/08/2004	08:00	PR Newswire (US)	Allos Therapeutics Reports Second Quarter 2004 Financial Results	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)

Apresentando as notícias mais relevantes sobre:NASDAQ:ALTH

<< Anterior 1 2 3 4 5 6 7 8 9 10 11 12 13 Próxima >>

Índice Bovespa

PÃO DE AÇUCAR ON

Neogrid Participacoes ON

MAGAZINE LUIZA ON

CM Hospitalar ON

LOJAS MARISA ON

Agrogalaxy Participacoes ON

Delayed Upgrade Clock

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições